<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5165">
  <stage>Registered</stage>
  <submitdate>3/04/2015</submitdate>
  <approvaldate>3/04/2015</approvaldate>
  <nctid>NCT02437916</nctid>
  <trial_identification>
    <studytitle>Safety Study of AMG 228 to Treat Solid Tumors</studytitle>
    <scientifictitle>A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20140131</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Malignancy</healthcondition>
    <healthcondition>Advanced Solid Tumors</healthcondition>
    <healthcondition>Cancer</healthcondition>
    <healthcondition>Oncology</healthcondition>
    <healthcondition>Oncology Patients</healthcondition>
    <healthcondition>Tumors</healthcondition>
    <healthcondition>Melanoma</healthcondition>
    <healthcondition>Non-small Cell Lung Cancer</healthcondition>
    <healthcondition>Squamous Cell Carcinoma of the Head and Neck</healthcondition>
    <healthcondition>Transitional Cell Carinoma of Bladder</healthcondition>
    <healthcondition>Colorectal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Head and neck</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AMG 228

Experimental: AMG 228 monotherapy - Part 1 and Part 2 of the study will both be with single agent AMG 228 in different selected tumor types.


Treatment: drugs: AMG 228
AMG 228 will be administered intravenously

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Subject incidence of dose limiting toxicities (DLT)</outcome>
      <timepoint>9 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Subject incidence of treatment-emergent adverse events</outcome>
      <timepoint>9 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Subject incidence of treatment-related adverse events</outcome>
      <timepoint>9 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Subject incidence of clinically significant changes in vital signs and physical assessments</outcome>
      <timepoint>9 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Subject incidence of clinically significant changes in ECGs</outcome>
      <timepoint>9 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Subject incidence of clinically significant changes in clinical laboratory tests</outcome>
      <timepoint>9 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>AMG 228 maximum observed concentration (Cmax)</outcome>
      <timepoint>9 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>AMG 228 minimum observed concentration (Cmin)</outcome>
      <timepoint>9 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>AMG 228 area under the concentration-time curve (AUC)</outcome>
      <timepoint>9 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>AMG 228 half-life (t1/2)</outcome>
      <timepoint>9 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Subject objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1</outcome>
      <timepoint>9 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of anti-AMG 228 antibody formation</outcome>
      <timepoint>9 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Activation status and changes in numbers of T regulator cells (Treg)</outcome>
      <timepoint>9 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject objective response per immune-related Response Criteria (irRC)</outcome>
      <timepoint>9 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Activation status of cytotoxic T lymphocytes (CTL)</outcome>
      <timepoint>9 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in numbers of cytotoxic T lymphocytes (CTL)</outcome>
      <timepoint>9 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject must have a pathologically documented, definitively diagnosed, advanced solid
             tumor

          -  Adequate hematological, renal, hepatic, and coagulation laboratory assessments</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Active autoimmune disease, history of autoimmune disease

          -  Treatment with immune modulators including

          -  Use of warfarin, factor Xa inhibitors, or direct thrombin inhibitors

          -  Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or
             investigational agent) within 28 days

          -  Major surgery within 28 days of study day 1</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>30</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Research Site - Parkville</hospital>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity,
      and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02437916</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>